Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2018 Dec 3. pii: S1083-8791(18)30798-5. doi: 10.1016/j.bbmt.2018.11.033. [Epub ahead of print]

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Author information

1
Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. Electronic address: yinamoto@ncc.go.jp.
2
Department of Ophthalmology, Zagreb University Clinical Hospital, Zagreb, Croatia.
3
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be the Match, Minneapolis, Minnesota.
4
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
5
Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
6
Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
7
Inselspital, Bern University Hospital, Bern, Switzerland.
8
Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota.
9
Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, California.
10
Indiana University Simon Cancer Center, Indianapolis, Indiana.
11
University of California, San Francisco, California.
12
Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
13
Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
14
Department of Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
15
University of Miami, Miami, Florida.
16
Center for International Blood and Marrow Transplant Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
17
Division of Pediatrics Hematology, Children's Hospital of Orange County, Orange, California.
18
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
19
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
20
Department of Clinical Neuroscience, Karolinska Institute, St Erik Eye Hospital, Stockholm, Sweden; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
21
University of Florida Health Shands Hospital, Gainesville, Florida.
22
Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
23
Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
24
Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
25
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
26
Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
27
Tufts Medical Center, Boston, Massachusetts.
28
Utah Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
29
Rush University Medical Center, Chicago, Illinois.
30
Divison of Hematology and Oncology, Department of Internal Medicine, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
31
Houston Methodist Hospital, Houston, Texas.
32
Lousiana State University Children's Hospital, New Orleans, Louisiana.
33
Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
34
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
35
Division of Hematology and Oncology, Mount Sinai Hospital, New York, New York.
36
Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland.
37
Hematology, University Hospital Basel, Basel, Switzerland.
38
Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
39
Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
40
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
41
Hematology Branch, Sarah Cannon Center for Blood Cancer, Nashville, Tennessee.
42
Hematopoietic Transplantation and Hemato-oncology Section, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
43
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
44
Department of Ophthalmology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.

Abstract

Non-graft-versus-host disease (GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT) but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

KEYWORDS:

Complication; Eye; Hematopoietic cell transplantation; Prevention; Review; Treatment

PMID:
30521975
DOI:
10.1016/j.bbmt.2018.11.033

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center